Who
Robert M. Plenge
Director
Company insider
Files Form 4 as: Director, BioMarin Pharmaceutical; EVP, Chief Research Officer, Bristol-Myers Squibb; Director, Translate Bio.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $45K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 10 Apr 2019
- Last trade
- 10 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Sep 2026filed 14 Sep 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,140 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,140 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —1,107 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,107 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,342 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,052 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,959 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —26,939 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —124 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $26K436 at $60.13 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,107 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,342 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,052 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,959 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers Squibboption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —26,939 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —2,342 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —253 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code F | $56K927 at $60.13 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code M | —14,052 at $0.00 | filing |
| 10 Mar 2026filed 12 Mar 2026 | BMY Bristol-Myers SquibbPharmaceuticals | SEC FORM 4 Code J | —6,900 at $0.00 | filing |
News
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in RevenueBMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?BMY · aol.com · 22 Oct 2026Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 VolatilityBMY · fool.com · 22 Oct 2026
0 headlines in the last 90 days name Robert M. Plenge; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.